


Name of Policy: <u>Polypharmacy</u> Policy Number: 3364-160-SD-129 Department: Psychiatry Approving Officer: Chief Executive Officer - UTMC Responsible Agent: Chair/Medical Director Department of Psychiatry Administrative Director Department of Psychiatry Scope: OP-Clinic-Psychiatry	 Effective Date: 11/01/2021 Initial Effective Date: 07/2004		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> <input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy </td> <td style="width: 50%; border: none;"> <input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy </td> </tr> </table>		<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy
<input type="checkbox"/> New policy proposal <input type="checkbox"/> Major revision of existing policy	<input type="checkbox"/> Minor/technical revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy		

(A) Policy Statement

The clinician will attempt to minimize the number of psychotropic medications that patients use while fully treating the target symptoms that have been identified.

(B) Purpose of Policy

To minimize the number of psychotropic medications prescribed to patients with severe and/or complicated psychiatric illness without neglecting full treatment of the target symptoms.

(C) Procedure

1. Clinician will be aware of the greater potential for side effects and drug interactions with an increasing number of medications especially if multiple agents in the same class are utilized, as well as the potential cost burden of using multiple medications.
2. Clinician will discuss the potential side effects of using multiple psychotropic medications which includes the risk of tardive dyskinesia with the patient and/or guardian when deciding the best medication options.

Approved by: <u>/s/</u> _____ 08/12/2021 Rick Swaine CPA Chief Executive Officer – UTMC Date <u>/s/</u> _____ 08/04/2021 Cheryl McCullumsmith, MD, PhD Chairman/Medical Director Department of Psychiatry/ODMH Certified Services Date <u>/s/</u> _____ 08/04/2021 Lindsay Watson MSW, LSW, MBA Administrative Director Department of Psychiatry Date <i>Review/Revision Completed By:</i> Agency Administration	Review/Revision Date: 08/2005 08/2007 10/2/2010 03/04/2014 1/10/2017 09/21/2018 07/06/2021 Next Review Date: 07/06/2024
Policies Superseded by This Policy: ODMH-SD-129	